|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn853707465 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
130312s2013 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020687659
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d YDXCP
|d OCLCF
|d EBLCP
|d D6H
|d AGLDB
|d VTS
|d AU@
|d STF
|d M8D
|d N$T
|d E7B
|d UKMGB
|d OCLCO
|d OCLCA
|d OCLCO
|d OCLCQ
|d OCLCO
|
| 016 |
7 |
|
|a 016416409
|2 Uk
|
| 019 |
|
|
|a 857078874
|
| 020 |
|
|
|a 9781626184503
|q ebook
|
| 020 |
|
|
|a 162618450X
|
| 020 |
|
|
|z 162618447X
|q hbk.
|
| 020 |
|
|
|z 9781626184473
|q hbk.
|
| 029 |
1 |
|
|a DEBBG
|b BV043776763
|
| 029 |
1 |
|
|a DEBSZ
|b 472793780
|
| 029 |
1 |
|
|a DEBBG
|b BV041572267
|
| 029 |
1 |
|
|a AU@
|b 000052265561
|
| 029 |
1 |
|
|a AU@
|b 000067551422
|
| 035 |
|
|
|a (OCoLC)853707465
|z (OCoLC)857078874
|
| 042 |
|
|
|a pcc
|
| 050 |
0 |
0 |
|a RC280.L8
|
| 060 |
1 |
4 |
|a WF 658
|b L963 2013
|
| 072 |
|
7 |
|a HEA
|x 039030
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 062000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 616.99424
|2 23
|
| 049 |
|
|
|a UAMI
|
| 245 |
0 |
0 |
|a Lung cancer :
|b a comprehensive overview /
|c Kathy Gately, editor.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2013]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer etiology, diagnosis and treatments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a Intro -- LUNG CANCER: A COMPREHENSIVE OVERVIEW -- Library of Congress Cataloging-in-Publication Data -- Contents -- Preface -- Chapter I: The Pathology of Lung Cancer -- Abstract -- Introduction -- Common Lung Cancers -- Adenocarcinoma -- Squamous Cell Carcinoma -- Distinction of Adenocarcinoma from Squamous Cell Carcinoma on Biopsy Specimens -- Small Cell Carcinoma -- Large Cell Carcinoma -- Neuroendocrine Tumours -- Metastases -- Other Tumours -- Staging -- Molecular Analysis -- Conclusion -- References -- Chapter II: Introduction to Lung Cancer, its Epidemiology and Diagnosis -- Abstract -- Introduction -- International Variation in Lung Cancer Prevalence -- Age and Lung Cancer -- Host Factors and Lung Cancer Risk from Smoking -- Gender Differences in Lung Cancer Incidence -- Race -- Second-Hand Tobacco Smoke -- Non-Smoking Related Exposures for Lung Cancer -- Radon -- Occupational Exposures -- Air Pollutants -- Body Mass Index as a Risk Factor for Lung Cancer -- Non-Cancer Lung Disease -- Genetic Factors in Lung Cancer Risk -- Diagnosis of Lung Cancer -- Symptomatic Lung Cancer Detection -- Asymptomatic Disease: Incidental and Screening Detection -- Diagnosis of Suspected Lung Cancer -- Diagnosis Based on Imaging Characteristics -- Diagnostic Strategies -- Conclusion -- References -- Chapter III: The Effect of Smoking Habit Intensity, Occupation and Diet on Lung Cancer Risk in Males -- Abstract -- Introduction -- Risk Factors -- Tobacco Smoking -- Occupational Exposure -- Diet -- Case Report -- Methods -- Results -- Conclusion -- References -- Chapter IV: Lung Cancer: Treatment in Early Stage -- Abstract -- Introduction -- Adjuvant and Neoadjuvant Therapy for Resectable Non-Small Cell Lung Cancer -- Evidence for Adjuvant CT -- Preoperative CT for Early-Stage NSCLC -- The Role of Adjuvant RT.
|
| 505 |
8 |
|
|a Future Directions: Targeted Therapies and Genetic Predictive and Prognostic Biomarkers -- Conclusion -- References -- Chapter V: Lung Cancer: Treatment in Advanced Stages -- Abstract -- Introduction -- Treatment of Stage III Non-Small Cell Lung Cancer (NSCLC) -- Treatment of Metastatic Non-Small Cell Lung Cancer -- Initial Systemic Therapy for Advanced NSCLC without an EGFR Mutation or the ALK Fusion Oncogene -- Initial Treatment with Targeted Agents -- Second Line Therapy -- Conclusion -- References -- Chapter VI: Management of Stage III N2 NSCLC -- Abstract -- Introduction -- Staging -- Proving N2 Disease -- Treatment -- Goals of Neoadjuvant Therapy -- Current Controversies -- Conclusion -- References -- Chapter VII: Targeted Therapies in Non-Small Cell Lung Cancer -- Abstract -- Introduction -- Targeted Therapy in Lung Cancer -- EGFR -- Targeting EGFR -- VEGF and VEGFR -- Targeting VEGFR with Bevacizumab -- Targeting VEGFR with TKIs -- EML4-ALK -- Targeting EML4-ALK -- KRAS -- Targeting KRAS -- HER2 -- Targeting HER2 -- B-RAF -- Targeting B-RAF -- C-Met -- Targeting C-Met -- PI3K -- Targeting PI3K -- MEK -- Targeting MEK -- PI3K and MEK Co-Targeted Inhibition -- IGF1R -- Targeting IGF1R -- The Future of Targeted Therapy -- Conclusion -- References -- Chapter VIII: Molecular Mechanisms of Cisplatin Resistance in Lung Cancer -- Abstract -- Introduction -- Resistance Mechanisms -- Epigenetic Regulation and Cisplatin Resistance -- Novel Strategies for Overcoming Cisplatin Resistance -- Conclusion -- References -- Chapter IX: Inflammation in Lung Carcinogenesis -- Abstract -- Introduction -- Cancer Related Inflammation -- Lung Cancer and Inflammation -- Inflammatory Mediators In Lung Cancer -- Targeting Inflammation as a Therapeutic Option -- Conclusion -- References.
|
| 505 |
8 |
|
|a Chapter X: The Link between Chronic Obstructive Pulmonary Disease and Lung Cancer: Novel Molecular Insights -- Abstract -- Introduction -- Hazardous Effects of Cigarette Smoking -- Carcinogenic Compounds in the Side-Stream Smoke -- Chronic Inflammation in COPD and Lung Cancer -- Genetics of COPD and Lung Cancer -- Epigenetic Phenomena and Cigarette Smoke -- Conclusion -- References -- Chapter XI: Diagnosis, Treatment and Follow-Up of Neoplastic Pericardial Disease in Lung Cancer -- Abstract -- Introduction -- Diagnosis -- Treatment -- Conclusion -- References -- Chapter XII: The Role of Claudin Proteins in Lung Tumorigenesis -- Abstract -- Introduction -- Claudin Family Proteins -- Post-Translational Modifications of Tight Junction Proteins -- Tight Junction Proteins and Lung Cancer -- Crosstalk of Claudins and Occludin with Other Signaling Pathways in Lung Cancer -- Claudins as Therapeutic Targets -- Conclusion -- Acknowledgments -- References -- Chapter XIII: The Role of the Arachidonic Acid Pathway in NSCLC Development and Progression: Novel Approaches for Therapeutic Intervention -- Abstract -- Introduction -- 1. Arachidonic Acid Metabolism: Generation and Classification of Eicosanoids -- 2. Altered Expression of Arachidonic Acid Signalling in NSCLC -- 3. Effect of the Arachidonic Acid Pathway on Tumour Cell Signalling and Proliferation -- 4. Arachidonic Acid Mediated Regulation of Tumour Cell Death -- 5. The Role of Arachidonic Acid Signalling in NSCLC Tumour Angiogenesis -- 6. Regulation of Adhesion, Migration and Invasion of NSCLC by Arachidonic Acid Pathways -- 7. Modulation of the Immune System in NSCLC by Arachidonic Acid -- 8. Targeting Arachidonic Acid Pathways Using Pharmacological and Natural Agents -- Conclusion -- References -- Index.
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Lungs
|x Cancer.
|
| 650 |
1 |
2 |
|a Lung Neoplasms
|
| 650 |
|
6 |
|a Poumons
|x Cancer.
|
| 650 |
|
7 |
|a HEALTH & FITNESS
|x Diseases
|x Cancer.
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL
|x Oncology.
|2 bisacsh
|
| 650 |
|
7 |
|a Lungs
|x Cancer
|2 fast
|
| 700 |
1 |
|
|a Gately, Kathy,
|e editor.
|
| 776 |
0 |
8 |
|i Print version:
|t Lung cancer
|d New York : Nova Science Publishers, [2013]
|z 162618447X (hbk.)
|w (DLC) 2013935077
|
| 830 |
|
0 |
|a Cancer etiology, diagnosis, and treatments.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=607834
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 10861096
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 607834
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL3022723
|
| 938 |
|
|
|a ebrary
|b EBRY
|n ebr10733905
|
| 994 |
|
|
|a 92
|b IZTAP
|
